CN112316017A - Gynecological antibacterial gel and preparation method thereof - Google Patents
Gynecological antibacterial gel and preparation method thereof Download PDFInfo
- Publication number
- CN112316017A CN112316017A CN202011303433.6A CN202011303433A CN112316017A CN 112316017 A CN112316017 A CN 112316017A CN 202011303433 A CN202011303433 A CN 202011303433A CN 112316017 A CN112316017 A CN 112316017A
- Authority
- CN
- China
- Prior art keywords
- parts
- gynecological
- water
- extract
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 13
- 238000001879 gelation Methods 0.000 title description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 16
- 229960001631 carbomer Drugs 0.000 claims abstract description 16
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 15
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 15
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 15
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000341 volatile oil Substances 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 210000003101 oviduct Anatomy 0.000 claims abstract description 10
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 7
- 241000218691 Cupressaceae Species 0.000 claims abstract description 7
- 229960002233 benzalkonium bromide Drugs 0.000 claims abstract description 4
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims abstract description 4
- 235000013311 vegetables Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 37
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 32
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 24
- 244000141009 Hypericum perforatum Species 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- 241000220317 Rosa Species 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 210000004877 mucosa Anatomy 0.000 abstract description 8
- 230000007794 irritation Effects 0.000 abstract description 5
- 239000000499 gel Substances 0.000 description 60
- 241000191967 Staphylococcus aureus Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 241000222122 Candida albicans Species 0.000 description 11
- 229940095731 candida albicans Drugs 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940126680 traditional chinese medicines Drugs 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241001052560 Thallis Species 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000212948 Cnidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 1
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The application relates to the field of antibacterial gel, and particularly discloses gynecological antibacterial gel and a preparation method thereof; the gynecological bacteriostatic gel comprises the following raw materials in parts by weight: 80-90 parts of radix sophorae flavescentis, 70-80 parts of golden cypress, 80-90 parts of fructus cnidii, 50-60 parts of gallnut, 40-50 parts of safflower, 1-2 parts of oviductus ranae, 1-2 parts of vegetable essential oil, 8-10 parts of glycerol, 10-15 parts of triethanolamine, 10-15 parts of carbomer, 2-3 parts of ethylparaben, 1-2 parts of benzalkonium bromide and the balance of water, and the balance is water and is added to the total amount of 1000 parts. The gynecological bacteriostatic gel has a good bacteriostatic effect and has no irritation effect on vaginal mucosa.
Description
Technical Field
The application relates to the field of bacteriostatic gels, in particular to a gynecological bacteriostatic gel and a preparation method thereof.
Background
Gynecological inflammation such as vaginitis, cervical erosion, etc. is a common disease and frequently encountered disease of women. One of the major current treatments for these gynecological inflammations is drug therapy. The common drug therapy comprises oral drugs and external therapy, and the external therapy mainly comprises suppository, effervescent agent administration treatment and traditional Chinese medicine fumigation and washing. Although the external therapy has a certain treatment effect, the use effect of patients is not ideal, for example, most of the medicines for treating cervical erosion are suppositories, the release of the medicine effect of the suppositories is slow, and the medicines are dissolved to form liquid which flows out of the vagina; effervescent agents can cause drying of the skin tissue surface, causing discomfort; the traditional Chinese medicine is inconvenient to use by fumigation.
Mucosal administration refers to the administration of a drug in intimate contact with the surface of a biological mucosa and into the circulatory system via epithelial cells. Mucosal administration has advantages such as avoidance of first-pass effect, balanced blood concentration, long action time, and small dosage and high bioavailability because of abundant submucosal capillaries. Chinese medicinal gel is a method for treating gynecological inflammation by mucosa administration which is emerging in recent years.
In view of the above-mentioned related technologies, the inventor considers that the existing traditional Chinese medicine gel has no obvious bacteriostatic effect, and needs to provide a gynecological bacteriostatic gel and a preparation method thereof.
Disclosure of Invention
In order to improve the bacteriostatic effect of the traditional Chinese medicine gel, the application provides a gynecological bacteriostatic gel and a preparation method thereof.
In a first aspect, the application provides a gynecological bacteriostatic gel, which adopts the following technical scheme:
the gynecological bacteriostatic gel comprises the following raw materials in parts by weight:
80-90 parts of radix sophorae flavescentis, 70-80 parts of golden cypress, 80-90 parts of fructus cnidii, 50-60 parts of gallnut, 40-50 parts of safflower, 1-2 parts of oviductus ranae, 1-2 parts of vegetable essential oil, 8-10 parts of glycerol, 10-15 parts of triethanolamine, 10-15 parts of carbomer, 2-3 parts of ethylparaben, 1-2 parts of benzalkonium bromide and the balance of water, and the balance is water and is added to the total amount of 1000 parts.
By adopting the technical scheme, the gynecological inflammation is usually caused by maladjustment of microbial flora in the vagina, and most of harmful bacteria in the vagina are staphylococcus aureus, escherichia coli and candida albicans. Radix Sophorae Flavescentis contains various alkaloids and flavonoids, and has effects of clearing heat and eliminating dampness; cortex Phellodendri contains berberine, and has effects of clearing heat, eliminating dampness, clearing pathogenic fire, and removing toxic substance; fructus Cnidii contains coumarin components, and has effects of dispelling pathogenic wind, removing dampness, killing parasites and relieving itching; galla chinensis contains tannic acid, and has effects of lowering fire and removing toxic substance; carthami flos contains flavone and volatile oil, and has effects of promoting blood circulation, dredging channels, removing blood stasis, and relieving pain. Because the five traditional Chinese medicines of the lightyellow sophora root, the golden cypress, the common cnidium fruit, the Chinese gall and the safflower are compatible, the five traditional Chinese medicines jointly play a role in inhibiting the growth of staphylococcus aureus, escherichia coli and candida albicans, and the oviductus ranae with the effects of preventing senility, nourishing yin and beautifying is supplemented, the gynecological bacteriostatic gel has a good bacteriostatic effect.
Optionally, the plant essential oil is rose essential oil.
By adopting the technical scheme, the rose essential oil not only has a nourishing effect, but also has an antibacterial effect on staphylococcus aureus, so that the antibacterial effect of the gynecological antibacterial gel is further improved.
Optionally, the gynecological antibacterial gel further comprises 0.5-1.5 parts by weight of nano-silver and 1-3 parts by weight of hypericum perforatum extract.
By adopting the technical scheme, the nano-silver and the hypericum perforatum have good bacteriostatic effects on staphylococcus aureus, escherichia coli and candida albicans, and the bacteriostatic effect of the gynecological bacteriostatic gel can be further improved by adding the nano-silver and the hypericum perforatum.
Optionally, the particle size of the nano silver is 20-50 nm.
By adopting the technical scheme, the particle size of the nano-silver is related to the bacteriostatic effect of the nano-silver, and the bacteriostatic effect of the gynecological bacteriostatic gel can be further improved by controlling the particle size of the nano-silver.
Optionally, the preparation method of the hypericum perforatum extract comprises the following steps: pulverizing herba Hyperici perforati, sieving to obtain coarse powder, adding 6-8 times of 80-85% ethanol solution, ultrasonic extracting for 1-2 hr, filtering, recovering ethanol from filtrate, and concentrating under reduced pressure to obtain extract with relative density of 1.10-1.20(60 deg.C), i.e. herba Hyperici perforati extract.
By adopting the technical scheme, the hypericum perforatum is ultrasonically extracted by ethanol, which is beneficial to the dissolution of antibacterial active ingredients such as hyperforin and aromatic oil ingredients, thereby further improving the antibacterial effect of the gynecological antibacterial gel.
Optionally, the weight ratio of the nano silver to the hypericum perforatum is 1: 2.
by adopting the technical scheme, the proportion of the nano-silver and the hypericum perforatum is controlled within a proper range, and the nano-silver and the hypericum perforatum are synergistic, so that the bacteriostatic effect of the gynecological bacteriostatic gel can be further improved.
In a second aspect, the application provides a preparation method of gynecological bacteriostatic gel, which adopts the following technical scheme:
a preparation method of gynecological bacteriostatic gel comprises the following steps:
s1: selecting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis, Carthami flos, and oviductus Ranae, cleaning;
dissolving ethylparaben in appropriate amount of ethanol to obtain ethylparaben solution for use;
soaking carbomer in appropriate amount of water for 24 hr to swell completely to obtain carbomer gel matrix;
s2: decocting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis and Carthami flos in water twice, mixing filtrates, concentrating to obtain extract with relative density of 1.10-1.20(60 deg.C), precipitating with ethanol, collecting supernatant, and recovering ethanol until no ethanol smell exists to obtain Chinese medicinal extract;
s3: adding ethylparaben solution and Chinese medicinal extract into carbomer gel matrix, adding other raw materials, stirring, adding water to desired volume, adding triethanolamine to adjust pH to 6-7, mixing, and packaging.
By adopting the technical scheme, the bacteriostatic gel prepared by the method has a good bacteriostatic effect.
Optionally, the specific conditions of decocting twice with water in S2 are as follows: adding 8-10 times of water for the first time, decocting for 1.5-2.5 hr, adding 6-8 times of water for the second time, decocting for 1-2 hr, and filtering.
By adopting the technical scheme, the decoction conditions are controlled, so that the dissolution of the bacteriostatic active ingredients in the traditional Chinese medicine is facilitated, and the bacteriostatic effect of the gynecological bacteriostatic gel is further improved.
In summary, the present application has the following beneficial effects:
1. the gynecological bacteriostatic gel has the beneficial effects that the five traditional Chinese medicines of the lightyellow sophora root, the golden cypress, the common cnidium fruit, the Chinese gall and the safflower are compatible, so that the five traditional Chinese medicines jointly play a role in inhibiting the growth of staphylococcus aureus, escherichia coli and candida albicans, and the oviductus ranae with the effects of preventing aging, nourishing yin and beautifying is supplemented, so that the gynecological bacteriostatic gel has a good bacteriostatic effect.
2. The application preferably adopts nano-silver and the hypericum perforatum extract, the nano-silver and the hypericum perforatum extract have an inhibiting effect on staphylococcus aureus, escherichia coli and candida albicans, and the nano-silver and the hypericum perforatum extract have a synergistic effect when being compounded, so that the bacteriostatic effect of the gynecological bacteriostatic gel can be further improved.
Detailed Description
The present application will be described in further detail with reference to examples.
Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 11229) and Candida albicans (ATCC 10231) were purchased from China center for culture Collection; tryptone, yeast extract, sodium chloride, sodium hydroxide, agar powder, glucose and ethanol are purchased from national medicine reagents GmbH; the nano silver is purchased from Shanghai Moghai Nscience and technology limited.
Preparation example of Hypericum perforatum extract
Preparation example 1
Pulverizing 100g of herba Hyperici perforati, sieving with 60 mesh sieve to obtain coarse powder, adding 6 times of 85% ethanol solution, ultrasonic extracting for 1 hr, filtering, recovering ethanol from filtrate, and concentrating under reduced pressure to obtain extract with relative density of 1.10-1.20(60 deg.C), i.e. herba Hyperici perforati extract.
Preparation example 2
Pulverizing 100g herba Hyperici perforati, sieving with 60 mesh sieve to obtain coarse powder, adding 8 times of 80% ethanol solution, ultrasonic extracting for 2 hr, filtering, recovering ethanol from filtrate, and concentrating under reduced pressure to obtain extract with relative density of 1.10-1.20(60 deg.C), i.e. herba Hyperici perforati extract.
Examples
Example 1
The formula of the gynecological bacteriostatic gel is shown in table 1. The preparation method comprises the following steps:
s1: selecting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis, Carthami flos, and oviductus Ranae, cleaning;
dissolving ethylparaben in 10ml ethanol solution to obtain ethylparaben solution for later use;
soaking carbomer in 50g of purified water for 24 hr to swell completely to obtain carbomer gel matrix;
s2: decocting five traditional Chinese medicines of radix sophorae flavescentis, golden cypress, fructus cnidii, gallnut and safflower twice by adding water, adding 8 times of water of the medicinal materials for the first time, decocting for 2.5 hours, adding 8 times of water of the medicinal materials for the second time, decocting for 1 hour, filtering, combining filtrates of the two times, concentrating until the relative density is 1.10-1.20(60 ℃), adding ethanol to enable the alcohol content to reach 75%, stirring and uniformly mixing, taking supernate, recovering ethanol until no alcohol taste exists, and obtaining a traditional Chinese medicine extract for later use;
s3: adding the ethylparaben solution and the Chinese medicinal extract into carbomer gel matrix, adding other raw materials, stirring, adding purified water to a sufficient amount, adding triethanolamine dropwise to adjust pH to 7, mixing, and packaging to obtain 2.5 g/piece.
Examples 2 to 3
The gynecological bacteriostatic gel is different from the gynecological bacteriostatic gel in the raw material proportion shown in the table 1.
TABLE 1 raw material ratios of examples 1-3
Raw materials (g) | Example 1 | Example 2 | Example 3 |
Sophora flavescens ait | 80 | 85 | 90 |
Cortex Phellodendri | 70 | 75 | 80 |
Fructus cnidii | 90 | 85 | 80 |
Galla chinensis | 60 | 55 | 50 |
Safflower carthamus | 40 | 45 | 50 |
Oviductus ranae oil | 2 | 1.5 | 1 |
Plant essential oil (mint) | 2 | 1.5 | 1 |
Glycerol | 8 | 9 | 10 |
Triethanolamine | 10 | 12 | 15 |
Carbomer | 10 | 12 | 15 |
Nipagin ethyl ester | 2 | 2.5 | 3 |
Benzalkonium bromide | 2 | 1.5 | 1 |
Purified water | 624 | 615 | 604 |
Example 4
A gynecological bacteriostatic gel, which is different from the gel in example 2 in that the essential oil of mint is replaced by the essential oil of rose.
Examples 5 to 9
A gynecological antibacterial gel, different from example 4, further comprises nano silver with a particle size of 100nm and/or Hypericum perforatum extract prepared in preparation example 1, and purified water is reduced by corresponding weight to make the total amount of gel be 1000 g. The ratio of nano silver to hypericum perforatum extract is shown in table 2.
TABLE 2 examples 5-9 compounding ratio of nano silver and/or Hypericum perforatum extract
Example 10
A gynecological bacteriostatic gel, which is different from the gynecological bacteriostatic gel in example 6 in that the particle size of nano silver is 20 nm.
Example 11
A gynecological bacteriostatic gel, which is different from the gynecological bacteriostatic gel in example 6 in that the particle size of nano-silver is 50 nm.
Example 12
A gynecological antibacterial gel comprises the same raw materials as in example 11, and the herba Hyperici perforati extract prepared in preparation example 2 is used. The preparation method comprises the following steps:
s1: selecting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis, Carthami flos, and oviductus Ranae, cleaning;
dissolving ethylparaben in 10ml ethanol to obtain ethylparaben solution for later use;
soaking carbomer in 50g of purified water for 24 hr to swell completely to obtain carbomer gel matrix;
s2: decocting five traditional Chinese medicines of radix sophorae flavescentis, golden cypress, fructus cnidii, gallnut and safflower twice by adding water, adding 10 times of water of the medicinal materials for the first time, decocting for 1.5 hours, adding 6 times of water of the medicinal materials for the second time, decocting for 2 hours, filtering, combining filtrates of the two times, concentrating until the relative density is 1.10-1.20(60 ℃), adding ethanol to enable the alcohol content to reach 75%, stirring and uniformly mixing, taking supernate, recovering ethanol until no alcohol taste exists, and obtaining a traditional Chinese medicine extract for later use;
s3: adding the ethylparaben solution and the Chinese medicinal extract into carbomer gel matrix, adding other raw materials, stirring, adding water to a sufficient amount, adding triethanolamine dropwise to adjust pH to 6, mixing, and packaging to obtain 2.5 g/piece.
Comparative example
Comparative example 1
The commercial Xiduo ylang tight gynecological gel.
Comparative example 2
Gynecological gel for treating gynecological inflammation is sold in the market.
Detection method
1. Bacteriostasis test
1.1 test sample: the gels of examples 1 to 12 and comparative examples 1 to 2 were taken as test samples 1 to 12 and control samples 1 to 2, respectively.
1.2 test strains: staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 11229), Candida albicans (ATCC 10231).
LB liquid medium: 10g of tryptone, 5g of yeast extract and 10g of sodium chloride, wherein the volume is up to 1000mL, the pH value is adjusted to 7 by using 1mol/L sodium hydroxide, and the components are subpackaged and sterilized by high-pressure steam at 121 ℃ for 20 min.
LB solid medium: adding 15g of agarose into LB liquid culture medium, subpackaging, and autoclaving at 121 deg.C for 20 min.
PDA culture medium: 200g of potatoes, 20g of glucose and 20g of agar, metering to 1000mL, subpackaging and sterilizing with high-pressure steam at 121 ℃ for 20 min.
Wherein the LB liquid culture medium and the LB solid culture medium are used for culturing staphylococcus aureus and escherichia coli, and the PDA culture medium is used for culturing candida albicans.
Selecting a ring of thalli from the thalli inclined plane after 2-3 times of activation, inoculating the thalli into a corresponding liquid culture medium, and putting the thalli into a constant-temperature oscillation incubator for culture, wherein the culture conditions of staphylococcus aureus and escherichia coli are 37 ℃ and 120 r/min; the culture conditions of Candida albicans were 28 deg.C, 150 r/min. When the bacteria grow to logarithmic growth phase, the concentration is adjusted to 5 x 10 by using a plate counting method5-5*106cfu/mL for use.
1.3 test methods: the results of the bacteriostatic ring test according to item 2.7.2 of the Disinfection Specification (2008 edition) are shown in Table 3.
TABLE 3 results of bacteriostasis
It can be seen by combining examples 1-3 and comparative examples 1-2 and table 3 that, although the gels of comparative examples 1 and 2 also have a certain bacteriostatic effect, the gels prepared in examples 1-3 have a better bacteriostatic effect than the commercially available gels, and have better inhibitory effects on staphylococcus aureus, escherichia coli and candida albicans.
As can be seen from examples 2 and 4 in combination with table 3, the gel containing rose essential oil has a slightly better bacteriostatic effect than the gel containing mint essential oil, especially the gel has a better inhibitory effect on staphylococcus aureus, which may be due to some bacteriostatic effect of rose essential oil on staphylococcus aureus.
As can be seen by combining examples 4-9 with Table 3, the bacteriostatic effect of the gel can be improved by adding either nano-silver alone or hypericum perforatum extract alone; from example 8, it can be seen that the nano-silver has a significant inhibitory effect on staphylococcus aureus, and from example 9, the hypericum perforatum extract has a significant inhibitory effect on candida albicans; as can be seen from the comparison of examples 5 to 7 and examples 8 to 9, the bacteriostatic effect of the gel simultaneously added with nano-silver and the hypericum perforatum extract is better than that of the gel separately added with nano-silver or hypericum perforatum extract, indicating that the nano-silver and the hypericum perforatum extract have synergistic effect and the ratio of nano-silver: the weight ratio of the hypericum perforatum extract is 1: 2, the gel has the best bacteriostatic effect.
Combining examples 6, 10, 11, and 12 and table 3, it can be seen that the particle size of the nano-silver also has a certain influence on the bacteriostatic effect, the smaller the particle size of the nano-silver is, the better the bacteriostatic effect of the gel is, but when the particle size of the nano-silver is smaller than a certain degree, the difference of the bacteriostatic effect is not large, and based on the consideration of the production cost, the nano-silver with the particle size range of 20-50nm is selected.
2. Irritation test of vaginal mucosa
2.1 test samples: 2 g of the gynecological bacteriostatic gel prepared in examples 1 to 12 were respectively put into an aseptic grinding pot to be ground and mixed uniformly to obtain test samples 1 to 12, and 2 g of the gynecological gel prepared in comparative examples 1 and 2 were put into an aseptic grinding pot to be ground and mixed uniformly to obtain control samples 1 to 2.
2.2 test animals: the first-class female big-ear Japanese white rabbit provided by the laboratory animals center of the medical college of Xian transportation university weighs 2.0-2.5 kg.
2.3 test methods: according to the protocol of the vaginal mucosa irritation test, item 2.3.5 of the Disinfection Specification (2002 edition).
4 rabbits were randomly divided into experimental and control groups of 2 animals each. Before the experiment, the vaginal orifice of each animal was checked for secretions, congestion and other lesions and the catheter was connected to a 5ml syringe. Fixing the experimental rabbit on the back, exposing perineum and vaginal orifice, wetting the catheter with test solution, gently inserting the catheter into vagina for 4-5 cm, slowly injecting 2ml of test solution with a syringe, and gently withdrawing the catheter. The control group was treated with physiological saline in the same manner. After 24 hours the animals were sacrificed by air embolism, the whole vagina was removed and cut longitudinally and the mucous membrane degeneration, secretion, vascular congestion, edema were visually observed. The animal injected with physiological saline is taken as a benchmark, the conditions of mucosal degeneration, blood vessel congestion and edema are scored as 0 point, the rest animals are scored in comparison with the animal injected with physiological saline, the score is 0-5 points, the damage is more serious when the score is larger, and the test result is shown in the table 4.
TABLE 4 vaginal mucosa irritation test results
Serial number | Degeneration of mucous membranes | Congestion of blood | Swelling of the stomach |
Example 1 | 0 | 0 | 0 |
Example 2 | 0 | 0 | 0 |
Example 3 | 0 | 0 | 0 |
Example 4 | 0 | 0 | 0 |
Example 5 | 0 | 0 | 0 |
Example 6 | 0 | 0 | 0 |
Example 7 | 0 | 0 | 0 |
Example 8 | 0 | 0 | 0 |
Example 9 | 0 | 0 | 0 |
Example 10 | 0 | 0 | 0 |
Example 11 | 0 | 0 | 0 |
Example 12 | 0 | 0 | 0 |
Comparative example 1 | 1 | 0 | 1 |
Comparative example 2 | 1 | 0 | 1 |
As can be seen by combining examples 1-12 with comparative examples 1-2 and by combining Table 4, the gels of comparative examples 1-2 have slight swelling and mucosal degeneration phenomena in the vaginal mucosa, whereas the gynecological bacteriostatic gels prepared in examples 1-12 have no irritation to the vaginal mucosa.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (8)
1. The gynecological bacteriostatic gel is characterized by comprising the following raw materials in parts by weight:
80-90 parts of radix sophorae flavescentis, 70-80 parts of golden cypress, 80-90 parts of fructus cnidii, 50-60 parts of gallnut, 40-50 parts of safflower, 1-2 parts of oviductus ranae, 1-2 parts of vegetable essential oil, 8-10 parts of glycerol, 10-15 parts of triethanolamine, 10-15 parts of carbomer, 2-3 parts of ethylparaben, 1-2 parts of benzalkonium bromide and the balance of water, and the balance is water and is added to the total amount of 1000 parts.
2. The gynecological bacteriostatic gel according to claim 1, wherein the plant essential oil is rose essential oil.
3. The gynecological bacteriostatic gel according to claim 1, which further comprises 0.5-1.5 parts by weight of nano-silver and 1-3 parts by weight of hypericum perforatum extract.
4. The gynecological bacteriostatic gel according to claim 3, wherein the particle size of the nano silver is 20-50 nm.
5. The gynecological bacteriostatic gel according to claim 3, wherein the preparation method of the hypericum perforatum extract comprises the following steps: pulverizing herba Hyperici perforati, sieving to obtain coarse powder, adding 6-8 times of 80-85% ethanol solution, ultrasonic extracting for 1-2 hr, filtering, recovering ethanol from filtrate, and concentrating under reduced pressure to obtain extract with relative density of 1.10-1.20(60 deg.C), i.e. herba Hyperici perforati extract.
6. The gynecological bacteriostatic gel according to claim 3, wherein the weight ratio of the nano-silver to the hypericum perforatum extract is 1: 2.
7. a process for preparing a gynaecological bacteriostatic gel according to any one of claims 1 to 6, comprising the steps of:
s1: selecting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis, Carthami flos, and oviductus Ranae, cleaning;
dissolving ethylparaben in appropriate amount of ethanol to obtain ethylparaben solution for use;
soaking carbomer in appropriate amount of water for 24 hr to swell completely to obtain carbomer gel matrix;
s2: decocting radix Sophorae Flavescentis, cortex Phellodendri, fructus Cnidii, Galla chinensis and Carthami flos in water twice, mixing filtrates, concentrating to obtain extract with relative density of 1.10-1.20(60 deg.C), precipitating with ethanol, collecting supernatant, and recovering ethanol until no ethanol smell exists to obtain Chinese medicinal extract;
s3: adding ethylparaben solution and Chinese medicinal extract into carbomer gel matrix, adding other raw materials, stirring, adding water to desired volume, adding triethanolamine to adjust pH to 6-7, mixing, and packaging.
8. The preparation method of the gynecological bacteriostatic gel according to claim 7, wherein the specific conditions of adding water and decocting twice in S2 are as follows: adding 8-10 times of water for the first time, decocting for 1.5-2.5 hr, adding 6-8 times of water for the second time, decocting for 1-2 hr, and filtering.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011303433.6A CN112316017A (en) | 2020-11-19 | 2020-11-19 | Gynecological antibacterial gel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011303433.6A CN112316017A (en) | 2020-11-19 | 2020-11-19 | Gynecological antibacterial gel and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112316017A true CN112316017A (en) | 2021-02-05 |
Family
ID=74321484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011303433.6A Pending CN112316017A (en) | 2020-11-19 | 2020-11-19 | Gynecological antibacterial gel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112316017A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344427A (en) * | 2022-01-21 | 2022-04-15 | 河北辰威健康管理有限公司 | Gynecological antibacterial gel |
CN114404359A (en) * | 2022-01-28 | 2022-04-29 | 湖南伟方生命科技有限公司 | Gynecological whitening and moistening nursing gel and preparation method thereof |
CN114652773A (en) * | 2022-04-22 | 2022-06-24 | 湖南省中医药研究院 | Gynecological gel and preparation method and application thereof |
CN114832057A (en) * | 2022-04-02 | 2022-08-02 | 朵博士健康科技(杭州)有限公司 | Bacteriostatic gynecological gel and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145073A (en) * | 2011-04-15 | 2011-08-10 | 吉林省中医药科学院 | Pharmaceutical composition for treating gynecological inflammation and preparation method thereof |
CN106938029A (en) * | 2016-01-05 | 2017-07-11 | 郑凯峰 | A kind of bacteriostatic gel and preparation method thereof |
CN109364143A (en) * | 2018-12-05 | 2019-02-22 | 新乡博凯生物技术有限公司 | A kind of gel cream and preparation method thereof |
CN109602695A (en) * | 2019-01-28 | 2019-04-12 | 拍合尔尼萨·吐尔孙 | A kind of production method of bacteriostatic gel |
CN110051773A (en) * | 2019-03-28 | 2019-07-26 | 刘化君 | A kind of gel and its preparation method that containing Camellia nitidissima there is antibacterial to repair cavity inflammation |
CN111184832A (en) * | 2020-02-24 | 2020-05-22 | 江西林丰药业有限公司 | Plant probiotic composition with functions of contracting vagina, lubricating, nourishing and protecting nests and preparation method thereof |
-
2020
- 2020-11-19 CN CN202011303433.6A patent/CN112316017A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145073A (en) * | 2011-04-15 | 2011-08-10 | 吉林省中医药科学院 | Pharmaceutical composition for treating gynecological inflammation and preparation method thereof |
CN106938029A (en) * | 2016-01-05 | 2017-07-11 | 郑凯峰 | A kind of bacteriostatic gel and preparation method thereof |
CN109364143A (en) * | 2018-12-05 | 2019-02-22 | 新乡博凯生物技术有限公司 | A kind of gel cream and preparation method thereof |
CN109602695A (en) * | 2019-01-28 | 2019-04-12 | 拍合尔尼萨·吐尔孙 | A kind of production method of bacteriostatic gel |
CN110051773A (en) * | 2019-03-28 | 2019-07-26 | 刘化君 | A kind of gel and its preparation method that containing Camellia nitidissima there is antibacterial to repair cavity inflammation |
CN111184832A (en) * | 2020-02-24 | 2020-05-22 | 江西林丰药业有限公司 | Plant probiotic composition with functions of contracting vagina, lubricating, nourishing and protecting nests and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
姚琳,等: "苦柏妇炎栓精制工艺优选", 《中国实验方剂学杂志》 * |
李玉杰,等: "玫瑰精油的化学成分及其抗菌活性", 《植物研究》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344427A (en) * | 2022-01-21 | 2022-04-15 | 河北辰威健康管理有限公司 | Gynecological antibacterial gel |
CN114404359A (en) * | 2022-01-28 | 2022-04-29 | 湖南伟方生命科技有限公司 | Gynecological whitening and moistening nursing gel and preparation method thereof |
CN114404359B (en) * | 2022-01-28 | 2024-04-02 | 湖南伟方生命科技有限公司 | Gynecological whitening and moisturizing nursing gel and preparation method thereof |
CN114832057A (en) * | 2022-04-02 | 2022-08-02 | 朵博士健康科技(杭州)有限公司 | Bacteriostatic gynecological gel and preparation method thereof |
CN114832057B (en) * | 2022-04-02 | 2024-01-16 | 朵博士健康科技(杭州)有限公司 | Antibacterial gynecological gel and preparation method thereof |
CN114652773A (en) * | 2022-04-22 | 2022-06-24 | 湖南省中医药研究院 | Gynecological gel and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112316017A (en) | Gynecological antibacterial gel and preparation method thereof | |
CN102145111B (en) | Traditional Chinese medicine composition for treating colpitis mycotica and preparation method thereof | |
CN113081928B (en) | Plant antibacterial gel and preparation method and application thereof | |
CN103860423B (en) | A kind of have collutory of anti-inflammation deodorize and its production and use | |
CN108853287B (en) | Pharmaceutical composition for resisting human papilloma virus and gynecological inflammation, gel preparation and application | |
CN104524021A (en) | Disinfectant for clinical laboratories and preparation method | |
CN113546142A (en) | Propolis bacteriostatic gel and preparation method thereof | |
CN111297961A (en) | Dong medicine for promoting wound healing | |
CN112245325A (en) | Health-care antibacterial gel and preparation method thereof | |
CN105613612A (en) | Agent for disinfecting intensive care unit and preparation method | |
CN109602813A (en) | A kind of bacteriostatic gel and preparation method thereof | |
CN105012818A (en) | Composition for treating gynecological inflammation and preparation and preparation method thereof | |
CN114306526B (en) | Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer | |
CN1524548A (en) | Liquid traditional Chinese medicine for treating skin disease and its preparation process | |
CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
CN1283391A (en) | Extracted liquor for disinfection | |
CN112999283A (en) | Gynecological lotion and preparation method thereof | |
Xu et al. | Application of Atractylodes Macrocephala Koidz Extract in Methicillin-Resistant Staphylococcus Aureus | |
CN114617837B (en) | Gynecological traditional Chinese medicine lotion and preparation method thereof | |
CN102670811B (en) | External medicament for treating bacterial vaginosis and colpitis mycotica | |
CN1462584A (en) | Externally-used disinfector | |
CN108578602B (en) | Traditional Chinese medicine composition for treating leukorrheal diseases and preparation method thereof | |
CN115569165B (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating bacterial prostatitis | |
CN105055622A (en) | Traditional Chinese medicine film-forming gel for treating shallow bed-sore at ulceration | |
CN1316991C (en) | Chinese traditional medicine in use for treating endometritis of cow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210205 |
|
RJ01 | Rejection of invention patent application after publication |